Breaking Down Barriers: Aurora Cannabis Eases Patient Access to High Quality Medical Cannabis Products in Australia
Aurora Cannabis (NASDAQ: ACB) has removed the concession card requirement for patients accessing its IndiMed medical cannabis products in Australia, expanding accessibility to all eligible patients in the market. Operating through its wholly-owned subsidiary MedReleaf Australia, this strategic move aims to create more seamless prescribing options in Australia's growing medical cannabis market.
IndiMed, launched in Australia in 2021 as the first concession product, has expanded its portfolio to include oil, dried flower products, and resin cartridges. The brand's flower products consistently rank among the top 10 most prescribed cannabis products for patients. MedReleaf Australia maintains TGA-GMP standards for quality and consistency.
The company has also filed a final short form base shelf prospectus with Canadian provincial securities regulators (except Quebec) and a corresponding shelf registration statement on Form F-10 with the SEC.
Aurora Cannabis (NASDAQ: ACB) ha rimosso il requisito della carta di concessione per i pazienti che accedono ai suoi prodotti di cannabis medica IndiMed in Australia, ampliando l'accessibilità a tutti i pazienti idonei nel mercato. Operando tramite la sua controllata interamente posseduta MedReleaf Australia, questa mossa strategica mira a creare opzioni di prescrizione più fluide nel crescente mercato della cannabis medica in Australia.
IndiMed, lanciato in Australia nel 2021 come primo prodotto con concessione, ha ampliato il suo portafoglio per includere oli, fiori secchi e cartucce di resina. I prodotti floreali del marchio si classificano costantemente tra i primi 10 prodotti di cannabis più prescritti per i pazienti. MedReleaf Australia mantiene standard TGA-GMP per qualità e coerenza.
L'azienda ha anche presentato un prospetto finale di base in forma abbreviata ai regolatori provinciali canadesi (eccetto il Quebec) e una corrispondente dichiarazione di registrazione sul modulo F-10 presso la SEC.
Aurora Cannabis (NASDAQ: ACB) ha eliminado el requisito de la tarjeta de concesión para los pacientes que acceden a sus productos de cannabis medicinal IndiMed en Australia, ampliando el acceso a todos los pacientes elegibles en el mercado. Operando a través de su subsidiaria de propiedad total MedReleaf Australia, este movimiento estratégico tiene como objetivo crear opciones de prescripción más fluidas en el creciente mercado de cannabis medicinal de Australia.
IndiMed, lanzado en Australia en 2021 como el primer producto de concesión, ha ampliado su cartera para incluir aceite, flores secas y cartuchos de resina. Los productos florales de la marca se clasifican consistentemente entre los 10 productos de cannabis más prescritos para los pacientes. MedReleaf Australia mantiene estándares TGA-GMP para calidad y consistencia.
La empresa también ha presentado un prospecto base final en forma corta a los reguladores de valores provinciales canadienses (excepto Quebec) y una declaración de registro correspondiente en el Formulario F-10 ante la SEC.
오로라 대마초 (NASDAQ: ACB)는 호주에서 IndiMed 의학용 대마초 제품에 접근하는 환자에 대한 양도카드 요구 사항을 제거하여 시장의 모든 적격 환자에게 접근성을 확대했습니다. MedReleaf Australia라는 완전 자회사로 운영되며, 이 전략적 조치는 호주의 성장하는 의학용 대마초 시장에서 보다 원활한 처방 옵션을 창출하는 것을 목표로 하고 있습니다.
2021년 호주에서 첫 양도 제품으로 출시된 IndiMed는 오일, 건조 꽃 제품 및 수지 카트리지를 포함하는 포트폴리오로 확장되었습니다. 이 브랜드의 꽃 제품은 환자에게 가장 많이 처방되는 대마초 제품 상위 10개 중 하나로 지속적으로 순위에 올라 있습니다. MedReleaf Australia는 품질과 일관성을 위해 TGA-GMP 기준을 유지합니다.
회사는 또한 캐나다 지방 증권 규제 기관(퀘벡 제외)에 최종 단기 기본 선전지를 제출했으며 SEC에 해당하는 F-10 양식으로 등록 성명서를 제출했습니다.
Aurora Cannabis (NASDAQ: ACB) a supprimé l'exigence de carte de concession pour les patients accédant à ses produits de cannabis médical IndiMed en Australie, élargissant ainsi l'accessibilité à tous les patients éligibles sur le marché. Opérant par l'intermédiaire de sa filiale entièrement détenue MedReleaf Australia, cette démarche stratégique vise à créer des options de prescription plus fluides sur le marché croissant du cannabis médical en Australie.
IndiMed, lancé en Australie en 2021 en tant que premier produit de concession, a élargi son portefeuille pour inclure des huiles, des fleurs séchées et des cartouches de résine. Les produits floraux de la marque figurent régulièrement parmi les 10 produits de cannabis les plus prescrits pour les patients. MedReleaf Australia maintient les normes TGA-GMP pour la qualité et la cohérence.
L'entreprise a également déposé un prospectus final abrégé auprès des régulateurs provinciaux canadiens (sauf au Québec) et une déclaration d'enregistrement correspondante sur le formulaire F-10 auprès de la SEC.
Aurora Cannabis (NASDAQ: ACB) hat die Anforderung einer Ermäßigungskarte für Patienten, die auf ihre medizinischen Cannabisprodukte IndiMed in Australien zugreifen, abgeschafft und damit den Zugang für alle berechtigten Patienten auf dem Markt erweitert. Das Unternehmen operiert über seine vollständig im Besitz befindliche Tochtergesellschaft MedReleaf Australia, und dieser strategische Schritt zielt darauf ab, nahtlosere Verschreibungsoptionen im wachsenden medizinischen Cannabismarkt Australiens zu schaffen.
IndiMed, das 2021 in Australien als erstes Erzeugnis mit Ermäßigung eingeführt wurde, hat sein Portfolio um Öle, getrocknete Blüten und Harzkartuschen erweitert. Die Blütenprodukte der Marke gehören konstant zu den zehn am häufigsten verschriebenen Cannabisprodukten für Patienten. MedReleaf Australia erfüllt die TGA-GMP-Standards für Qualität und Konsistenz.
Das Unternehmen hat außerdem ein endgültiges Kurzprospekt bei den kanadischen Provinzaufsichtsbehörden (außer Quebec) eingereicht und eine entsprechende Shelf-Registrierungsmitteilung auf dem Formular F-10 bei der SEC eingereicht.
- Expanded market access by removing concession card requirement in Australia
- IndiMed products rank in top 10 most prescribed cannabis flowers in Australia
- Product portfolio diversification with oils, flowers, and resin cartridges
- Filing of shelf prospectus suggests potential future dilutive financing
Insights
The removal of concession card requirements for IndiMed products in Australia marks a strategic pivot that could significantly expand Aurora's market reach. Australia's medical cannabis market, valued at approximately
Several key factors make this development particularly significant:
- Market Access Expansion: By eliminating the concession requirement, Aurora has effectively expanded its addressable market from a subset to the entire Australian medical cannabis patient population, estimated at over 300,000 active patients.
- Competitive Positioning: IndiMed's consistent ranking in the top 10 prescribed flowers, combined with this access expansion, positions Aurora to potentially capture a larger market share. The TGA-GMP compliance ensures product quality standards that create barriers to entry for competitors.
- Strategic Timing: This move aligns with Australia's evolving regulatory landscape, where medical cannabis prescription pathways are becoming more streamlined. The timing suggests Aurora's deep understanding of market dynamics and regulatory trends.
The concurrent filing of a shelf prospectus, while not immediately impacting operations, provides Aurora with financial flexibility for potential market opportunities. This could be particularly relevant for scaling operations in response to expected increased demand in the Australian market.
The strategic importance of this move extends beyond immediate market access. It positions Aurora to capitalize on Australia's role as a gateway to the broader Asia-Pacific medical cannabis market, where regulatory frameworks are gradually evolving. The company's demonstrated ability to navigate international regulatory requirements and quickly adapt to market needs suggests strong execution capabilities in global expansion efforts.
NASDAQ | TSX: ACB
Largest Global Medical Cannabis Company Operating in Nationally Regulated Markets, Aurora Removes Concession Card Requirements to Access IndiMed Products in
"This change to open up patient access to MedReleaf's IndiMed products reflects our dedication to supporting prescribers by creating more seamless and simplified prescribing options," said Andre Jerome, Executive Vice President, Global Business Development at Aurora. "It is a testament to our unmatched expertise in navigating international markets that we have the ability to quickly adapt and apply necessary change with ease, in order to meet patient demand in the rapidly growing medical cannabis market in
IndiMed was first launched in
MedReleaf Australia, a wholly owned subsidiary of Aurora, is committed to quality, consistency and proudly meets all TGA-GMP standards. For further information about the company's offerings, doctors and health care professionals can contact MedReleaf Australia's clinical support team or visit their website: www.medreleafaustralia.com.au.
In addition, the Company announced it has filed a final short form base shelf prospectus with securities regulators in each of the provinces of Canada, except Quebec, and a corresponding shelf registration statement on Form F–10 with the United States Securities and Exchange Commission.
This news release does not constitute an offer of any securities for sale.
About Aurora Cannabis Inc.
Aurora is opening the world to cannabis, serving both the medical and consumer markets across
Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".
Forward Looking Information:
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the removal of the concession card requirement for patients to access medical cannabis products under the Company's IndiMed brand and the associated impact on the access to products for patients in
These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in
View original content to download multimedia:https://www.prnewswire.com/news-releases/breaking-down-barriers-aurora-cannabis-eases-patient-access-to-high-quality-medical-cannabis-products-in-australia-302377404.html
SOURCE Aurora Cannabis Inc.
FAQ
What changes did Aurora Cannabis (ACB) make to IndiMed access in Australia?
When was IndiMed first launched in Australia by Aurora Cannabis (ACB)?
What products are included in Aurora Cannabis's (ACB) IndiMed portfolio in Australia?
How does IndiMed rank among prescribed cannabis flowers in Australia?
What regulatory standards does MedReleaf Australia comply with?
